Clinical-stage focus With NA-831 and NA-704 in clinical development and a Phase 2A completed for NA-831, there is an opportunity to engage couple of early-adopter clinics and specialty centers seeking innovative Alzheimer’s therapies and to align with long-readout timelines for trial planning and site partnerships.

Oral and IV options The portfolio includes an oral formulation (NA-831) and an IV weekly regimen (NA-704), plus an advanced MICROS Controlled Release Infusion System for hospital and homecare delivery, enabling multi-channel sales conversations with physicians, infusion centers, and hospital systems.

Delivery technology MICROS Infusion System's approval for marketing in the USA creates a potential add-on sales angle with pharmacotech and device distributors, offering bundled solutions for neurodegenerative therapy delivery and improved adherence in Alzheimer’s patient populations.

Small company agility As a small, privately held biotech subsidiary with a global parent, NeuroActiva can leverage nimble partnerships, co-development agreements, and fast decision cycles to collaborate with contract research organizations, specialty pharmacies, and biotech licensors to accelerate trials and market entry.

Market positioning Competitively position NA-831 and NA-704 against other neurodegenerative programs by highlighting safety signals from Phase 2A, potential neuroprotection and neurogenesis benefits, and the unique infusion delivery option to differentiate in clinician and patient engagement efforts.